# Advanced Flower Capital Inc.: financial statements, quarterly

AFCG · Nasdaq · CIK 1822523 · [Other](/sectors/other.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/afcg.md) · [Financials](/companies/afcg/financials.md) · [Filings](/companies/afcg/filings.md) · [Insiders](/companies/afcg/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/afcg/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [15.3](/filings/0001822523-24-000045.md) | [15.7 d](/filings/0001822523-25-000003.md) | [12.7](/filings/0001822523-25-000016.md) | [16.4](/filings/0001822523-25-000027.md) | [8.9](/filings/0001628280-25-051319.md) | [7.6 d](/filings/0001628280-26-014392.md) | [6.6](/filings/0001628280-26-031692.md) | [6.2](/filings/0001628280-26-056471.md) | [6.5](/filings/0001628280-25-051319.md) | [5.2 d](/filings/0001628280-26-014392.md) | not reported | not reported |
| Interest expense | $m | [1.5](/filings/0001822523-24-000045.md) | [1.6 d](/filings/0001822523-25-000003.md) | [1.6](/filings/0001822523-25-000016.md) | [1.6](/filings/0001822523-25-000027.md) | [1.6](/filings/0001628280-25-051319.md) | [1.6 d](/filings/0001628280-26-014392.md) | [1.8](/filings/0001628280-26-031692.md) | [1.9](/filings/0001628280-26-056471.md) | [1.6](/filings/0001628280-25-051319.md) | [1.5 d](/filings/0001628280-26-014392.md) | [1.7](/filings/0001628280-26-031692.md) | [1.9](/filings/0001628280-26-056471.md) |
| Income tax | $m | [0.7](/filings/0001822523-24-000045.md) | [0.7 d](/filings/0001822523-25-000003.md) | [0.2](/filings/0001822523-25-000016.md) | [0.3](/filings/0001822523-25-000027.md) | [0.4](/filings/0001628280-25-051319.md) | [(0.4) d](/filings/0001628280-26-014392.md) | [0.1](/filings/0001628280-26-031692.md) | [(0.1)](/filings/0001628280-26-056471.md) | [(0.9)](/filings/0001628280-25-051319.md) | [0.3 d](/filings/0001628280-26-014392.md) | [0.6](/filings/0001628280-26-031692.md) | [0.5](/filings/0001628280-26-056471.md) |
| Net income | $m | [8.0](/filings/0001822523-23-000032.md) | [(9.2) d](/filings/0001822523-24-000014.md) | [(0.1)](/filings/0001822523-24-000019.md) | [16.4](/filings/0001822523-24-000037.md) | [1.4](/filings/0001628280-25-051319.md) | [(1.0) d](/filings/0001628280-26-014392.md) | [4.1](/filings/0001628280-26-031692.md) | [(13.2)](/filings/0001628280-26-056471.md) | [(12.5)](/filings/0001628280-25-051319.md) | [0.9 d](/filings/0001628280-26-014392.md) | [11.4](/filings/0001628280-26-031692.md) | [5.4](/filings/0001628280-26-056471.md) |
| Diluted EPS | $ per share | [0.39](/filings/0001822523-24-000045.md) | not reported | [(0.01)](/filings/0001822523-25-000016.md) | [0.80](/filings/0001822523-25-000027.md) | [0.06](/filings/0001628280-25-051319.md) | not reported | [0.18](/filings/0001628280-26-031692.md) | [(0.60)](/filings/0001628280-26-056471.md) | [(0.57)](/filings/0001628280-25-051319.md) | not reported | [0.49](/filings/0001628280-26-031692.md) | [0.23](/filings/0001628280-26-056471.md) |
| Basic EPS | $ per share | [0.39](/filings/0001822523-24-000045.md) | not reported | [(0.01)](/filings/0001822523-25-000016.md) | [0.80](/filings/0001822523-25-000027.md) | [0.06](/filings/0001628280-25-051319.md) | not reported | [0.18](/filings/0001628280-26-031692.md) | [(0.60)](/filings/0001628280-26-056471.md) | [(0.57)](/filings/0001628280-25-051319.md) | not reported | [0.49](/filings/0001628280-26-031692.md) | [0.23](/filings/0001628280-26-056471.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss, us-gaap:ProfitLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [73.2](/filings/0001822523-23-000032.md) | [90.4](/filings/0001822523-25-000003.md) | [82.3](/filings/0001822523-24-000019.md) | [170](/filings/0001822523-24-000037.md) | [122](/filings/0001822523-24-000045.md) | [104](/filings/0001628280-26-014392.md) | [3.3](/filings/0001822523-25-000016.md) | [3.4](/filings/0001822523-25-000027.md) | [45.1](/filings/0001628280-25-051319.md) | [38.6](/filings/0001628280-26-056471.md) | [113](/filings/0001628280-26-031692.md) | [107](/filings/0001628280-26-056471.md) |
| Total assets | $m | [445](/filings/0001822523-23-000032.md) | [467](/filings/0001822523-25-000003.md) | [476](/filings/0001822523-24-000019.md) | [458](/filings/0001822523-24-000037.md) | [367](/filings/0001822523-24-000045.md) | [402](/filings/0001628280-26-014392.md) | [322](/filings/0001822523-25-000016.md) | [291](/filings/0001822523-25-000027.md) | [289](/filings/0001628280-25-051319.md) | [276](/filings/0001628280-26-056471.md) | [395](/filings/0001628280-26-031692.md) | [400](/filings/0001628280-26-056471.md) |
| Total liabilities | $m | [106](/filings/0001822523-23-000032.md) | [147](/filings/0001822523-25-000003.md) | [166](/filings/0001822523-24-000019.md) | [144](/filings/0001822523-24-000037.md) | [161](/filings/0001822523-24-000045.md) | [201](/filings/0001628280-26-014392.md) | [121](/filings/0001822523-25-000016.md) | [106](/filings/0001822523-25-000027.md) | [119](/filings/0001628280-25-051319.md) | [100](/filings/0001628280-26-056471.md) | [209](/filings/0001628280-26-031692.md) | [212](/filings/0001628280-26-056471.md) |
| Shareholders' equity | $m | [339](/filings/0001822523-24-000045.md) | [320](/filings/0001628280-26-014392.md) | [311](/filings/0001822523-25-000027.md) | [314](/filings/0001628280-25-051319.md) | [206](/filings/0001628280-25-051319.md) | [201](/filings/0001628280-26-056471.md) | [201](/filings/0001628280-26-056471.md) | [185](/filings/0001628280-26-056471.md) | [169](/filings/0001628280-25-051319.md) | [176](/filings/0001628280-26-056471.md) | [186](/filings/0001628280-26-056471.md) | [187](/filings/0001628280-26-056471.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [5.5 d](/filings/0001822523-24-000045.md) | [6.2 d](/filings/0001822523-25-000003.md) | [6.4](/filings/0001822523-25-000016.md) | [10.3 d](/filings/0001822523-25-000027.md) | [2.6 d](/filings/0001628280-25-051319.md) | [2.2 d](/filings/0001628280-26-014392.md) | [3.9](/filings/0001628280-26-031692.md) | [1.8 d](/filings/0001628280-26-056471.md) | [6.1 d](/filings/0001628280-25-051319.md) | [(0.6) d](/filings/0001628280-26-014392.md) | [(30.8)](/filings/0001628280-26-031692.md) | [(6.2) d](/filings/0001628280-26-056471.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [20.1](/filings/0001822523-23-000032.md) | [20.5](/filings/0001822523-24-000019.md) | [20.3](/filings/0001822523-24-000037.md) | [20.3](/filings/0001822523-24-000045.md) | [20.4](/filings/0001822523-25-000016.md) | [20.4](/filings/0001822523-25-000027.md) | [20.8](/filings/0001628280-25-051319.md) | [22.1](/filings/0001628280-26-031692.md) | [22.1](/filings/0001628280-26-056471.md) | [22.2](/filings/0001628280-25-051319.md) | [23.5](/filings/0001628280-26-031692.md) | [23.2](/filings/0001628280-26-056471.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 22,671,919 at 2026-08-07, from the cover of the [10-Q filed 2026-08-13](/filings/0001628280-26-056471.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.